19 / 62
1
Overall survival
Clinical data cut-off date: April 24, 2018, 11 months after the last patient was enrolled. CI, confidence interval. HR, hazard ratio; CP/ET, carboplatin + etoposide.
Adapted from The New England Journal of Medicine, Horn L, et al, First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer, Epub ahead of
print.
No. at risk
Atezolizumab 201 191 187 182 180 174 159 142 130 121 108 92 74 58 46 33 21 11 5 3 2 1
Placebo
202 194 189 186 183 171 160 146 131 114 96 81 59 36 27 21 13 8 3 3
2
2
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Months
100
90
80
70
60
50
40
30
20
10
0
Overall survival (%)
12-month OS
51.7%
38.2%
Atezolizumab
+ CP/ET
Placebo
+ CP/ET
Censored
+
Atezolizumab
+ CP/ET
(N = 201)
Placebo
+ CP/ET
(N = 202)
OS events — no. (%)
104 (51.7)
134 (66.3)
Median OS — months
(95%
CI)
12.3
(10.8, 15.9)
10.3
(9.3, 11.3)
HR (95% CI)
0.70
(0.54, 0.91)
p = 0.0069
Median follow-up, months
13.9